Healius Ltd

Healthcare AU HLS


Last update at 2024-05-29T02:55:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -397.30000M 416.90M 167.80M 46.40M 83.20M
Minority interest - - - - -
Net income -367.80000M 307.90M 43.70M -70.50000M 55.90M
Selling general administrative 864.30M 951.40M 856.30M 838.20M 1137.60M
Selling and marketing expenses - - - - -
Gross profit 1483.20M 2019.50M 1630.10M 1381.30M 1598.00M
Reconciled depreciation 277.20M 278.50M 247.30M 218.00M 68.70M
Ebit 34.10M 432.40M 221.40M 56.50M 117.40M
Ebitda 311.30M 710.90M 468.70M 274.50M 186.10M
Depreciation and amortization 277.20M 278.50M 247.30M 218.00M 68.70M
Non operating income net other - - - - -
Operating income 98.10M 484.40M 270.80M 86.10M 117.40M
Other operating expenses 263.30M 775.30M 672.60M 662.10M 1692.90M
Interest expense 28.60M 15.50M 53.60M 0.10M 34.20M
Tax provision -17.30000M 122.90M 101.50M -25.60000M 24.80M
Interest income 62.30M 50.50M 62.90M 52.40M 25.10M
Net interest income -62.30000M -50.50000M -87.60000M 0.10M -34.20000M
Extraordinary items 12.20M 13.90M -22.60000M -142.50000M -1.90000M
Non recurring - - - - -
Other items - - - - -
Income tax expense -17.30000M 122.90M 101.50M -25.60000M 27.30M
Total revenue 1706.90M 2336.20M 1900.70M 1584.60M 1804.50M
Total operating expenses 1385.10M 1531.60M 1388.20M 1307.90M 1486.40M
Cost of revenue 223.70M 316.70M 270.60M 203.30M 206.50M
Total other income expense net -433.10000M -20.50000M 13.50M 2.60M -34.20000M
Discontinued operations 12.20M 13.90M -22.60000M -142.50000M -1.90000M
Net income from continuing ops -380.00000M 294.00M 66.30M 72.00M 55.90M
Net income applicable to common shares -367.80000M 307.90M 43.70M -70.50000M 55.30M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 3653.20M 4136.80M 3782.20M 4566.50M 3350.80M
Intangible assets 73.10M 75.20M 76.30M 79.30M 77.90M
Earning assets - - - - -
Other current assets 31.60M 70.80M 40.80M 26.10M 31.50M
Total liab 2147.00M 2215.20M 1924.90M 2635.20M 1295.40M
Total stockholder equity 1506.20M 1921.60M 1857.30M 1931.30M 2055.40M
Deferred long term liab - - - - -
Other current liab 0.90M 5.70M 52.30M 447.90M 6.90M
Common stock 2421.00M 2422.90M 2572.00M 2672.30M 2671.10M
Capital stock 2421.00M 2422.90M 2572.00M 2672.30M 2671.10M
Retained earnings -923.30000M -521.20000M -731.60000M -737.60000M -608.10000M
Other liab 14.40M 18.60M 22.50M 74.20M 96.50M
Good will 1897.50M 2344.30M 2042.30M 2040.20M 2482.50M
Other assets 87.90M 74.60M 82.20M 82.40M 118.20M
Cash 115.30M 81.30M 70.10M 137.50M 119.70M
Cash and equivalents - - - - -
Total current liabilities 629.60M 641.30M 684.70M 972.80M 391.90M
Current deferred revenue 147.70M 242.30M 196.50M 139.20M 161.50M
Net debt 1650.70M 1697.70M 1372.00M 1619.90M 678.20M
Short term debt 263.00M 223.70M 230.00M 183.40M 0.60M
Short long term debt - - 5.60M 9.50M 6.90M
Short long term debt total 1766.00M 1779.00M 1442.10M 1757.40M 797.90M
Other stockholder equity -1497.70000M -1901.70000M -1844.00000M -1934.70000M -7.60000M
Property plant equipment 1243.30M 1270.90M 1244.90M 1043.60M 327.00M
Total current assets 344.30M 371.80M 330.90M 1319.80M 346.50M
Long term investments 7.10M 5.80M 5.60M 1.20M 0.60M
Net tangible assets -464.40000M -497.90000M -261.30000M -188.20000M -509.30000M
Short term investments - - - - -
Net receivables 164.60M 219.70M 184.10M 176.10M 151.20M
Long term debt 562.10M 606.10M 258.10M 810.10M 797.10M
Inventory 32.80M 49.20M 35.90M 26.90M 22.70M
Accounts payable 218.00M 169.60M 205.90M 202.30M 222.90M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 8.50M 19.90M 16.90M -3.40000M -7.60000M
Additional paid in capital - - - - -
Common stock total equity - - - 2672.30M 2671.10M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - -3.60000M - -
Accumulated amortization - - - - -
Non currrent assets other - - - 8.00M 44.20M
Deferred long term asset charges - - - - -
Non current assets total 3308.90M 3765.00M 3451.30M 3246.70M 3004.30M
Capital lease obligations 1203.90M 1172.90M 1177.60M 937.80M 0.80M
Long term debt total 1503.00M 1555.30M 1211.30M 1574.00M 797.30M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments 67.30M -401.70000M 386.90M -121.90000M 9.90M
Change to liabilities 44.80M -33.60000M -57.60000M 61.40M 9.40M
Total cashflows from investing activities 67.30M -401.70000M 386.90M -121.90000M -217.50000M
Net borrowings -261.80000M 131.10M -758.80000M -171.40000M -66.00000M
Total cash from financing activities -366.60000M -176.50000M -984.70000M -192.60000M 125.70M
Change to operating activities -31.60000M 2.50M 34.40M 23.80M -17.20000M
Net income -367.80000M 307.90M 43.70M -70.50000M 55.90M
Change in cash 34.00M 8.60M -71.80000M 24.80M 35.70M
Begin period cash flow 81.30M 72.70M 144.50M 119.70M 84.00M
End period cash flow 115.30M 81.30M 72.70M 144.50M 119.70M
Total cash from operating activities 333.30M 586.80M 525.90M 406.90M 127.60M
Issuance of capital stock - - - - 244.00M
Depreciation 262.60M 265.00M 237.00M 246.10M 68.70M
Other cashflows from investing activities 143.40M -308.20000M -10.00000M -26.50000M -87.70000M
Dividends paid 34.30M 98.10M 56.30M 21.20M 52.30M
Change to inventory 14.50M -12.40000M -8.90000M -4.60000M 0.20M
Change to account receivables 52.60M -33.00000M 46.10M -74.40000M -18.60000M
Sale purchase of stock -8.90000M -139.40000M -97.50000M -97.50000M 244.00M
Other cashflows from financing activities -278.40000M 61.00M -242.00000M -171.40000M 130.00M
Change to netincome 431.80M 40.30M 127.20M 179.90M 42.00M
Capital expenditures 76.10M 93.50M 61.30M 72.40M 100.00M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 67.10M -45.40000M 37.20M -79.00000M 1.20M
Stock based compensation -7.80000M 7.90M 13.70M 9.60M -
Other non cash items 438.50M 13.90M 245.20M 231.30M -124.60000M
Free cash flow 257.20M 493.30M 464.60M 334.50M 27.60M


  • Previous Close 1.30
  • Market Cap959.22M
  • Volume1439018
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA107.20M
  • Revenue TTM1691.80M
  • Revenue Per Share TTM2.92
  • Gross Profit TTM 554.30M
  • Diluted EPS TTM-1.65

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Healius Ltd
-0.045 3.46% 1.25 - 21.10 0.52 0.84 1.43 -3.5527
Sonic Healthcare Ltd
-0.23 0.94% 24.25 22.74 17.92 1.55 1.69 1.96 10.59
Integral Diagnostics Ltd
0.01 0.41% 2.45 - 19.12 1.22 1.85 1.97 71.46
Monash IVF Group Ltd
0.03 1.77% 1.44 23.67 - 2.40 2.05 2.89 13.15
Australian Clinical Labs Ltd
0.05 2.31% 2.21 27.50 13.35 0.75 3.09 1.22 5.27

Reports Covered

Stock Research & News


Healius Limited provides specialty diagnostic services to consumer and practitioners in Australia. The company operates through three segments: Pathology, Imaging, and Others. It offers diagnostic imaging services, private medical laboratory, and pathology services. It also provides cataract surgery, colonoscopy, gastroscopy, plastic and cosmetic surgery, skin cancer removal, IVF egg collection, and gynaecological surgery services under the Laverty Pathology, Dorevitch Pathology, QML Pathology, Western Diagnostic Pathology, Genomic Diagnostic, Vetpath Laboratory, Vetnostics, QML Vetnostics, TML Vetnostics, ASAP Laboratory, Abbott Pathology, TML Pathology, IQ, Pathology, Kossard, Gastrolab, and Agilex Biolabs; Lumus Imaging; and Montserrat brands. The company was formerly known as Primary Health Care Limited and changed its name to Healius Limited in December 2018. Healius Limited was incorporated in 1994 and is based in Sydney, Australia.

Healius Ltd

Liberty Place, Sydney, NSW, Australia, 2000

Key Executives

Name Title Year Born
Dr. Malcolm W. Parmenter B.S., M.A.I.C.D., M.S. MD, CEO & Director 1955
Ms. Maxine Jaquet CFO & COO NA
Mr. John McKechnie Chief Exec. of the Pathology Division NA
Mr. Rob Phipps Group Exec. of People & Culture and Sustainability NA
Mr. Henry Barclay Chief Exec. of Day Hospitals NA
Mr. Charles Tilley B.Sc., FCIS, L.L.B., B.Sc. (Hons), LLB (Hons) Company Sec. NA
Ms. Alison Stephenson Additional Company Sec. NA
Ms. Janet Payne Group Exec. of Corp. Affairs NA
Dr. John Houston Advisor NA
Ms. Maxine Jaquet B.Com. MD, CEO & Director NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).